FindTrial
Sign In

To study if vitamin D supplementation in vitamin D deficient patients of rheumatoid arthritis impproves vascular function in them. Vascular function predicts risk of cardiovascular diseases in them and will be measured by flow mediated dilation of brachial artery.

Impact of vitamin D supplementation on vascular function in patients with rheumatoid arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012846
Enrollment
25
Registered
2018-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients of rheumatoid arthritis, those who are either in remission or have low disease activity and are vitamin D deficient shall be recruited for the study

Interventions

Intervention1: Vitamin D3(Cholecalciferol) 300,000 IU: Tablet Vitamin D3 300,000 IU will be given to vitamin D deficient patients, orally at week 16 and 24 of the study Control Intervention1: No treat

Sponsors

PGIMER Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years and up to 70 years 2. Vitamin D deficient [serum 25(OH) D levels

Exclusion criteria

Exclusion criteria: 1. Patients with high disease activity as defined by CDAI >22. 2. Patients with Diabetes mellitus. 3. Presence of Heart failure[NYHA Class 3 and 4] 4. Recent adverse CVD events[CAD/ACS/CVA within 1 month] 5. Subjects with known malignancies 6. Active smokers 7. Patients with hypercalcemia [>=10.5 mg/dL] 8. Patients who have taken vitamin D in therapeutic doses within 30 days of start of study period.

Design outcomes

Primary

MeasureTime frame
Improvement in brachial artery Flow mediated dilatation (FMD) at Week 32 as compared to week 16Timepoint: Improvement in brachial artery Flow mediated dilatation (FMD) at Week 32 as compared to week 16—

Secondary

MeasureTime frame
1. Improvement in brachial artery Flow mediated dilatation (FMD) at Week 32, as compared to baseline 2. Decrease in CRP at Week 32, as compared to baseline and Week 16 Timepoint: 1. Improvement in brachial artery Flow mediated dilatation (FMD) at Week 32, as compared to baseline 2. Decrease in CRP at Week 32, as compared to baseline and Week 16—

Countries

India

Contacts

Public ContactDr Vikas Sharma

PGIMER, Chandigarh

amansharma74@yahoo.com9814219779

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026